Clinical magnetic hyperthermia requires integrated magnetic particle imaging

Sean Healy; Andris F Bakuzis; Patrick W Goodwill; Anilchandra Attaluri; Jeff W M Bulte; Robert Ivkov

doi:10.1002/wnan.1779

Clinical magnetic hyperthermia requires integrated magnetic particle imaging

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 May;14(3):e1779. doi: 10.1002/wnan.1779. Epub 2022 Mar 3.

Authors

Sean Healy^{1

2}, Andris F Bakuzis³, Patrick W Goodwill⁴, Anilchandra Attaluri⁵, Jeff W M Bulte^{1

6

7

8

9}, Robert Ivkov^{2

9

10

11}

Affiliations

¹ Department of Biomedical Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
² Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
³ Instituto de Física and CNanoMed, Universidade Federal de Goiás, Goiânia, GO, Brazil.
⁴ Magnetic Insight, Inc., Alameda, California, USA.
⁵ Department of Mechanical Engineering, Pennsylvania State University, Harrisburg, Harrisburg, Pennsylvania, USA.
⁶ Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, Maryland, USA.
⁷ Cellular Imaging Section and Vascular Biology Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁸ Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
⁹ Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
¹⁰ Department of Materials Science and Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
¹¹ Department of Mechanical Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland, USA.

Abstract

Magnetic nanomaterials that respond to clinical magnetic devices have significant potential as cancer nanotheranostics. The complexities of their physics, however, introduce challenges for these applications. Hyperthermia is a heat-based cancer therapy that improves treatment outcomes and patient survival when controlled energy delivery is combined with accurate thermometry. To date, few technologies have achieved the needed evolution for the demands of the clinic. Magnetic fluid hyperthermia (MFH) offers this potential, but to be successful it requires particle-imaging technology that provides real-time thermometry. Presently, the only technology having the potential to meet these requirements is magnetic particle imaging (MPI), for which a proof-of-principle demonstration with MFH has been achieved. Successful clinical translation and adoption of integrated MPI/MFH technology will depend on successful resolution of the technological challenges discussed. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Diagnostic Tools > In Vivo Nanodiagnostics and Imaging.

Keywords: Cancer; magnetic fluid hyperthermia; magnetic nanoparticles; magnetic particle imaging; theranostics.

Publication types

Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Diagnostic Imaging / methods
Humans
Hyperthermia, Induced* / methods
Magnetic Phenomena
Magnetite Nanoparticles* / therapeutic use
Neoplasms* / diagnostic imaging
Neoplasms* / therapy

Substances

Magnetite Nanoparticles

Abstract

Publication types

MeSH terms

Substances

Grants and funding